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ABSTRACT
Background: Radiotherapy technology continues to advance and the expectation of improved out-
comes requires greater accuracy in various radiotherapy steps. Different factors affect the overall accur-
acy of dose delivery. Institutional comprehensive quality assurance (QA) programs should ensure that
uncertainties are maintained at acceptable levels. The International Atomic Energy Agency has recently
developed a report summarizing the accuracy achievable and the suggested action levels, for each
step in the radiotherapy process.
Overview of the report: The report seeks to promote awareness and encourage quantification of
uncertainties in order to promote safer and more effective patient treatments. The radiotherapy pro-
cess and the radiobiological and clinical frameworks that define the need for accuracy are depicted.
Factors that influence uncertainty are described for a range of techniques, technologies and systems.
Methodologies for determining and combining uncertainties are presented, and strategies for reducing
uncertainties through QA programs are suggested. The role of quality audits in providing international
benchmarking of achievable accuracy and realistic action levels is also discussed.
Recommendations: The report concludes with nine general recommendations:
(1) Radiotherapy should be applied as accurately as reasonably achievable, technical and biological
factors being taken into account.
(2) For consistency in prescribing, reporting and recording, recommendations of the International
Commission on Radiation Units and Measurements should be implemented.
(3) Each institution should determine uncertainties for their treatment procedures. Sample data are
tabulated for typical clinical scenarios with estimates of the levels of accuracy that are practically
achievable and suggested action levels.
(4) Independent dosimetry audits should be performed regularly.
(5) Comprehensive quality assurance programs should be in place.
(6) Professional staff should be appropriately educated and adequate staffing levels should be
maintained.
(7) For reporting purposes, uncertainties should be presented.
(8) Manufacturers should provide training on all equipment.
(9) Research should aid in improving the accuracy of radiotherapy. Some example research projects
are suggested.
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Recent technological developments have allowed for a transi-
tion from two-dimensional (2D) radiotherapy to the
implementation of 3D conformal radiotherapy (CRT), inten-
sity-modulated radiotherapy (IMRT) including volumetric arc
therapy (VMAT), image-guided radiotherapy (IGRT), adaptive
radiotherapy (ART), and 4D imaging and motion manage-
ment in radiotherapy [1–3]. Brachytherapy procedures have
also evolved [4,5] both for high dose rate (HDR) techniques
as well as permanent implants, especially for prostate cancer
treatments. Multiple imaging modalities are now available for
target volume and normal tissue delineation in radiation
treatment planning, both for external beam radiotherapy
(EBRT) and brachytherapy. These new technologies are often
combined with an integrated computerized radiation infor-
mation system allowing cancer centers to operate as fully
networked environments. The pace of new advancements in
technologies and the expectation of improved outcomes
have resulted in a recognized need for greater accuracy and
oversight in the radiation treatment process [6].
The degree of application of the various technologies
within radiotherapy varies dramatically across the world with
these variations not only occurring from one country to
another, but also within some individual countries.
Independent of the level of technological sophistication,
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accuracy in radiotherapy and the means by which it is esti-
mated, achieved and maintained, remain central to the treat-
ment process. In order to sustain the required accuracy in
dose delivery, all steps of the radiotherapy process should be
covered by comprehensive quality assurance (QA) programs.
It is well recognized that there is a need to evaluate the
influence of different factors affecting the accuracy of radi-
ation dose delivery, and to define the actions necessary to
maintain treatment uncertainties at acceptable levels [7].
While a number of reports and publications have defined
accuracy needs in radiotherapy, most of these reports were
developed in an era with different radiotherapy technologies
[8–12]. In addition to technological changes and advances in
dosimetry, significant data have been published on clinical
studies using these new technologies. In the meantime, there
have also been developments in QA methodologies, including
improvements of dosimetry techniques and standards.
Furthermore, the published accuracy requirements were par-
tially based on clinical information and clinical procedures
available prior to the days of modern image-based technolo-
gies. In view of these new planning and delivery technologies,
improvements in geometric and dosimetric assessment meth-
odologies, and the availability of new clinical dose-volume
data [13], an international guidance document on accuracy
requirements and uncertainties in radiotherapy was devel-
oped by the International Atomic Energy Agency (IAEA) to
promote awareness and encourage quantification of uncer-
tainties, thus allowing for safer and more effective patient
treatments [14]. The intent of this paper is to provide a high
level summary of this IAEA report such that the radiotherapy
community will have an increased awareness of its existence,
and may profit from its recommendations.
The uncertainties addressed in the report [14] begin with
the assumption of a specified medical prescription. The
report focuses on how accurately the prescription can be
delivered and the associated uncertainties in dose determin-
ation for both tumor and normal tissues. Physician variation
in target volume definition is not considered. Uncertainties in
clinical decisions regarding diagnosis, stage and comorbid-
ities are considered in the radiobiology section of the report
as factors that may influence the dose-response curve. In
other words, the report focuses on uncertainties related to
the imaging, treatment planning and dose delivery process.
Inevitably as part of an uncertainty discussion, QA issues
are raised although the report does not address QA codes of
practice or guidelines, many of which have been well docu-
mented by various professional societies and organizations.
The emphasis is on raising an awareness of accuracy and
uncertainty issues such that the treatment process can be
optimized and appropriately communicated, to the ultimate
benefit of the patient.
Although it is well recognized that uncertainties in the
radiation dose delivery process have an impact on clinical
outcome, the actual measurement of that outcome has its
own uncertainties. Clinical outcome uncertainties are beyond
the scope of the report and are not addressed.
The report begins with a brief description of the radio-
therapy process for EBRT and brachytherapy, followed by a
description of the terminology that is important to accuracy
considerations. The rationale for determining accuracy
requirements is outlined from radiobiological and
clinical perspectives. A review is given of publications provid-
ing practically attainable accuracy in both EBRT and brachy-
therapy. After a discussion on managing uncertainties nine
general recommendations are provided.
Overview of the report
The radiotherapy process
Within the radiotherapy process itself, a multidisciplinary team
is necessary and consists of a radiation oncologist, medical
physicist and radiation therapist, and in some countries a dosi-
metrist (i.e. a treatment planner). Each member of this team is
responsible for different aspects of the entire radiotherapy
process. The accurate delivery of multiple radiation treatment
fractions is influenced largely by the reproducibility of patient
setup and the dosimetric and technical accuracy of the radi-
ation treatment machines, associated accessories and the
work flow in the department. Furthermore, the accurate clin-
ical implementation of the treatment plan is dependent on
the accuracy and completeness of the documentation and the
knowledge, skills and attitudes of all the members of the
radiotherapy multidisciplinary team. What is crucial in radio-
therapy is the co-existence of equipment quality control (QC)
procedures along with best clinical practice; independently,
they will not achieve the required outcome.
Radiobiology perspective
Dose-response curves in radiotherapy describe the relation-
ship between the dose and the incidence of a specific type
of radiation induced endpoint, be it tumor or normal tissue-
related. The steepness of the dose-response curve, c, repre-
sents the change in response, in percent, for a 1% change in
dose anywhere along the dose-response curve, e.g. c50 corre-
sponds to 50% response. Summary data are provided in the
report for c50 and show that late responding normal tissues
have a steeper c50 (of the order of 2–6) compared to tumors
(1.5–2.5). Quite often values of 4 and 2, respectively, are used
for illustrative purposes.
Caveats regarding published steepness estimates include:
1. Patient series with heterogeneity in characteristics of
patient, tumor and dose will result in shallower (less
steep) dose-response curves with lower c values.
2. Bias in non-randomized studies appear to yield higher
c50 values compared to randomized trials as bias tends
to overestimate the effect of radiotherapy.
3. c values for adjuvant therapy are much lower than those
derived from a definitive radiotherapy.
In a relatively heterogeneous population, a reduced
accuracy will have relatively less impact than uncertainty at
the individual patient level. The number of patients
required in randomized controlled clinical trials is strongly
dependent on the steepness of the dose-response curve
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and the uncertainty in dose delivery. Clinical trials that
have larger uncertainties therefore require many more
patients.
Selected examples are given in the report to illustrate
how different types of inaccuracy can affect outcome, and a
general sense of the required accuracy in radiotherapy is
then given. Detailed consideration is given to tumor
response being near the top of the dose-response curves,
and to normal tissue response being near the bottom.
Although no simple hard rules can be given, radiobiological
modeling shows that it is reasonable to strive for accuracies
in systematic bias in dose delivery of 1–2%. For random
uncertainties, the modeling shows that if the increase in tox-
icity is limited to <3%, the dose uncertainties need to be
restricted to <5% and<3% for c50 equal to 4 and 6, respect-
ively. To ensure a reasonably low loss of tumor control
and/or increase in toxicity, a reasonable goal would be to
aim for<5% in random uncertainty (rD). In well stratified
patient populations, as could occur in clinical trials, this limit
should probably be tightened to rD< 3% to meet a 3% max-
imum deterioration of outcome. Based on modeling of geo-
metric uncertainty, aiming for a 3% loss in tumor control
probability, the volume missing 10% of the planned dose
should be kept <12% and<6% for c50¼ 1.8 and 4.0,
respectively.
Clinical perspective
The clinical framework and evidence base for making rational
decisions has an impact on accuracy in the radiotherapy pro-
cess. International recommendations, systems and guidelines
should be applied, e.g. International Commission on
Radiation Units and Measurements (ICRU) reports for volume
definitions, international disease classification systems for
staging and published scoring systems for outcomes. At the
institutional level, policies should be based on evidence-
based medicine and/or consensus guidelines, and the radio-
therapy prescription, dosimetry, delivery and verification
should be formulated and audited in a multidisciplinary set-
ting. There is a need for site-specific studies to correlate
imaging and pathology for targets as well as the develop-
ment of anatomical consensus atlases, interdisciplinary review
of clinical practice, including inter- and intra-clinician variabil-
ity in volume definition, and the need for training in volume
definition when transitioning to more advanced image-based
technologies. For repeated imaging during ART, for instance,
the dose level and imaging modality should be recorded
when modifying volumes to assess the need for re-planning
patients.
Levels of accuracy practically achievable (dosimetric,
geometric and technical perspective)
The report provides an extensive review of published work
on the levels of accuracy that have been determined in the
clinical environment. In order to provide a comprehensive
overview of accuracy as it relates to a range of different
systems and processes in radiotherapy (EBRT and
brachytherapy), the determination of accuracy is approached
from the following perspectives:
 Reference dosimetry – The framework used for the dis-
semination of standards in radiation metrology is
described and the uncertainties applicable to the current
reference standards used in radiotherapy are given for
brachytherapy and EBRT with low, medium and high
energy x-ray beams. In the clinical environment, reference
beam calibration can be confirmed using dosimetry audits
and an overview of the uncertainties obtained in beam
calibration of high energy photon beams from the
IAEA/WHO TLD postal dose audit system is given [15].
Also, ensuring a small uncertainty in the dosimetry of
small and non-standard beams is of importance, in par-
ticular for stereotactic and IMRT treatments, including
VMAT. This was emphasized in Recommendation 9 as a
suggested area of research.
 Relative dosimetry and dose calculations including
treatment planning systems – Achievable accuracy in
the radiotherapy commissioning process is considered
including results obtained from audits of treatment plan-
ning systems (TPSs) that use different calculation algo-
rithms; one important criterion in the uncertainty
evaluation is the TPS capability of accounting for the
transport of secondary electrons.
 Patient positioning and immobilization – The initial
definition of the patient position and the ability to accur-
ately reproduce this position on a daily basis is crucial for
the accurate delivery of a course of treatment. With the
current trend towards higher overall dose, higher dose
per fraction and smaller margins around the tumor vol-
ume, care and attention to patient preparation is of even
greater significance. The optimum patient position and
method of immobilization is based on the clinical site, the
extent of the tumor volume, the technology and the tech-
nique. The implementation of immobilization devices
includes detailed documentation of reference points.
There should be an institutional reference system for
associating the table position with the immobilization and
positioning devices. Indexed systems facilitate this process
but require compatibility between the devices and the
tabletop (usually all indexed immobilization devices will
then need to be purchased from one supplier). Patient
repositioning uncertainties are dependent on the body
site and the immobilization devices used. Methodologies
for verifying daily patient setup are discussed in the
report. Notwithstanding the need for determining setup
accuracy at the institutional level, the setup accuracy
achievable for various anatomic sites using different
immobilization devices are tabulated, based on a litera-
ture review [16].
 Imaging systems – Imaging for radiotherapy is generally
performed for treatment planning purposes before the
treatment is started and for positioning, verification,
evaluation and re-planning purposes during the course
of treatment. Imaging for treatment planning purposes
is often performed using dedicated modalities such as
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computed tomography (CT), positron emission tomog-
raphy (PET)/CT and magnetic resonance imaging (MRI)
scanners, or simulators in separate rooms. Imaging per-
formed during treatment for positioning and verification
purposes is usually performed using equipment in the
treatment room. The uncertainties related to imaging in
the radiotherapy process are primarily of a geometric
nature. The report provides an overview of the accuracy
achievable on imaging equipment used for treatment
planning as well as for treatment verification.
 Treatment delivery systems and processes – Given the
wide diversity of resources currently available globally, it
is important for a radiotherapy department to define the
levels of accuracy that can be realistically achieved and to
use this information both to inform current practice and
to identify future improvements. In this way more com-
plex techniques will be introduced when an appropriate
environment exists. In defining the level of accuracy
achievable, sources of uncertainty such as equipment-
and patient-related procedures, staffing levels and work
organization should be reviewed, the weak links identi-
fied, and consideration should be given as to how they
will be addressed. Staff responsible for treatment delivery
should understand the scientific basis of radiotherapy and
the importance, therefore, of accurate delivery. They
should be conscious of what they are doing, consider
how best to do it and be aware of the consequences of
not doing it correctly. Only in this way can a culture of
accuracy in treatment delivery, irrespective of resource
constraints, be assured. The clinical aspects of QA includ-
ing routine peer review meetings and regular chart
rounds can lessen the likelihood of errors in routine tasks
from a lack of due attention. All staff should therefore be
encouraged to participate in a comprehensive QA pro-
gram. It is also important that the staff understands the
radiobiology underpinning treatment interruptions if they
are to ensure that these are managed effectively in the
department. Consideration must be given to the timing of
the start of treatment and this should ideally be at the
beginning of the working week. Starting treatment just
before a weekend adds at least two days to the overall
treatment time. A policy must be developed to manage
unscheduled gaps and all staff should be involved in this
process if it is to be implemented successfully. The
policy should include recommendations on scheduling,
managing scheduled downtime and its impact, and how
to compensate for interruptions in treatment when they
occur.
The summary of estimates of EBRT and brachytherapy-
related uncertainties is available in Supplementary Tables I
and II, where dosimetric and spatial uncertainties are listed,
as well as uncertainties in CT numbers, together with rele-
vant action levels. For example, acceptable levels of differen-
ces between the measured and planned dose at the dose
specification point vary between 3.5% and 5%. End-to-end
tests with anthropomorphic phantoms have yielded an
uncertainty in dose delivery of 5% (k¼ 1); thus, considering
additional patient-related uncertainties, 5% is likely an under-
estimate for real patient treatments [17].
Managing uncertainty
Quality management is essential and although it does not
guarantee accuracy in radiation treatment, it does improve
the likelihood that accurate treatments will be provided. One
of the significant concerns regarding accuracies and uncer-
tainties in radiotherapy is the question of how much time,
energy and effort, needs to be put into improving accuracy
and reducing uncertainties in radiotherapy. Although it is
well recognized that previous statements on accuracy
requirements were predicated both on dose-response consid-
erations and on what accuracy is reasonably achievable, the
issue of quantifying ‘what is reasonable’ is just at its infancy.
The most relevant metric is clinical outcome. However, one
of the best ways to determine outcome is through clinical tri-
als, and clinical trial successes themselves are dependent on
the accuracy and uncertainties in dose delivery. More
research and more results from clinical studies are required
to assess the capabilities of radiobiological models to predict
clinical outcome. In the meantime, such models and their
parameters should be used knowledgeably and with extreme
caution, especially if they are implemented clinically in treat-
ment planning.
In order to minimize the clinical impact of dose- and treat-
ment-related uncertainties, the professionals involved must
have some understanding of the magnitude of the uncertain-
ties that exist within their own clinical context and for their
specific treatment procedures. For treatment planning, treat-
ment delivery and other aspects of treatment technology,
such uncertainties are generally derived from commissioning
and QC procedures. A proper recording of the data will give
variations in the results over time. Third party independent
dose audit procedures will give a sense of accuracy in beam
dosimetry, although end-to-end tests will provide information
about the overall accuracy of the planning and delivery of a
specific treatment technique. However, what is much more
difficult to determine are individual patient- and treatment-
related uncertainties. It is the magnitude of these uncertain-
ties that allows determination of the site- and technique-spe-
cific clinical target volume (CTV) to planning target volume
(PTV) margin at an institutional level.
IAEA TECDOC 1588 [18] indicates that one of the mile-
stones to transition from 2D radiotherapy to 3D CRT or to
IMRT is to perform an estimation of setup uncertainties so
that 3D margins can be determined. Such uncertainties can
be determined by some form of verification imaging of the
patient in the treatment position on the treatment machine
[19]. This imaging could be performed using electronic por-
tal imaging devices and extended to full daily in-room 3D
image-guidance. Increased levels of sophistication should
aim to provide greater accuracy in order to allow a reduc-
tion in CTV to PTV margin – the magnitude of which is
largely governed by the combined systematic errors. An off-
line portal imaging strategy can then be used to verify the
patient setup and to reduce these systematic errors.
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An online correction strategy capable of detecting target
and/or organ position can additionally monitor and control
both the systematic and random errors associated with
organ motion.
The reporting and presentation of uncertainties in 3D dose
distributions continues to be a challenge [20]. This is partly
due to the large amount of data that exists within a 3D dose
distribution, and partly because of the complexity of assessing
different magnitudes of uncertainties within different regions
of the irradiated patient. The routine display and documenta-
tion of uncertainties in TPSs also remains a challenge with no
methods being implemented on commercial TPSs. This
remains an area of research and clinical implementation.
To reduce uncertainties in the clinic it is essential that
written directives, guidelines and procedures exist integrated
within a comprehensive quality management system, in par-
ticular for those issues that have an influence on the accur-
acy of patient treatment. Furthermore, documentation and
communication should be unambiguous to guarantee opti-
mal treatment and to avoid incidents and near misses. Each
center should therefore have a safety reporting and learning
system, which is a legal requirement in many countries, and
continuous analysis of the events reported is necessary. The
extensiveness and reliability of such a system will depend on
the readiness to report incidents and near misses, and to dis-
cuss them openly. First, different categories are needed to be
defined to account for the severity of the incident, which will
have a large influence on the follow-up procedure. An
important aspect of a safety reporting and learning system is
that all information should be handled confidentially. In add-
ition, education, training and continuing education of the
radiotherapy team members are of critical importance for a
successful quality system.
Audits in radiotherapy are an important component of
assuring accuracy for both EBRT and brachytherapy.
Dosimetry audits for both reference and non-reference condi-
tions, remote and on-site, internal and external, as well as
partial and comprehensive, are being developed as technol-
ogy matures and techniques develop. In addition, compre-
hensive clinical audits such as QUATRO [21] are also
becoming more established within the healthcare sector.
Criteria for different levels of clinical audits in radiotherapy
can be developed for infrastructure and resources, the proc-
esses and the outcomes. Criteria can be generic to cover a
wide range of situations or can be specific to the individual
audit situation. They can help to carry out a more detailed
analysis of a problem if this is required. Criteria are typically
arrived at through expert consensus and focus groups in
order to derive the best measure of service quality.
Recommendations
The following general recommendations are based on:
1. Accuracy and uncertainty considerations for the total
radiotherapy process for both EBRT and brachytherapy.
2. The rationale for determining accuracy requirements
including radiobiological, clinical, technical and dosimet-
ric perspectives.
3. Baseline levels of accuracy that are practically attainable
both in EBRT and brachytherapy.
4. Methods on managing uncertainties to maintain them at
acceptable levels.
Recommendation 1: as accurately as reasonably
achievable
All forms of radiotherapy should be applied as accurately as
reasonably achievable (AAARA), technical and biological factors
being taken into account.
Different clinical scenarios may require different levels of
dosimetric and spatial accuracy.
Recommendation 2: ICRU recommendations
For consistency in prescribing, recording and reporting of EBRT
and brachytherapy, the recommendations of the ICRU should
be implemented. When relevant, the recommendations of other
recognized consensus groups should be implemented.
Recommendation 3: levels of accuracy that are
practically achievable
The data found in Supplementary Tables I and II for EBRT and
brachytherapy, respectively, should be used as a guide for esti-
mating the levels of accuracy that are practically achievable.
The tables also provide suggested action levels in cases where
deviations occur that are significantly beyond the normal range
of values.
Note that these data are for common clinical scenarios. It
should be emphasized that Recommendation 1 has priority.
Although it is extremely difficult to include every treatment
scenario in a single table with precise quantitative data,
Table I does provide a sample that could be considered in
every institution and a local version should be developed
that includes typical accuracies that are possible along with
action levels.
Recommendation 4: dosimetry audits
An independent dosimetry audit should be performed for every
new installation that is about to embark on radiation treat-
ments. In addition, regular (e.g. annual) audits should be per-
formed using remote services or on-site visits (or equivalent).
Recommendation 5: comprehensive quality assurance
A comprehensive QA program should be in place in every
radiotherapy department. Routine QC procedures should be
implemented in accordance with published recommendations
and local regulatory requirements.
Recommendation 6: staffing, education and training
Professional staff should have appropriate education and train-
ing. Staffing levels should be adequate to ensure safe and
ACTA ONCOLOGICA 5
accurate delivery of the radiation doses. The radiotherapy staff
should also have the support of the institution’s administrative
leadership.
Recommendation 7: clinical trials and reporting
uncertainties
For reporting purposes, as part of clinical trials, publications,
etc., the uncertainties associated with the relevant quantities
and parameters should be estimated and presented.
This recommendation is quoted from ICRU Report 83 [20]
and is repeated here as it is very relevant to the context of
this publication.
Recommendation 8: applications training on
radiotherapy equipment
Manufacturers of radiotherapy equipment should provide
detailed operating and applications training for all equipment,
recognizing that the final responsibility associated with clinical
implementation lies with the professionals in the clinical
departments.
Recommendation 9: research
A number of areas of research are mentioned throughout the
report and should be pursued to aid with improvements in pro-
viding accurate and safe radiotherapy with reduced uncertainties.
Examples of research areas that may lead to more accur-
ate radiotherapy include: display of uncertainties as part of
the planning process, probabilistic definition of CTV, clarify-
ing the PTV concept for brachytherapy, application of radio-
biological models in the treatment planning process, cost-
benefit analyses, small field dosimetry and consistent descrip-
tion of inter- and intra-clinician variability in defining target
volumes.
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